Fibroblast-Restricted Inflammasome Activation Promotes Atrial Fibrillation and Heart Failure With Diastolic Dysfunction
- PMID: 40243956
- PMCID: PMC12434206
- DOI: 10.1016/j.jacbts.2025.02.004
Fibroblast-Restricted Inflammasome Activation Promotes Atrial Fibrillation and Heart Failure With Diastolic Dysfunction
Abstract
Atrial fibrillation (AF) often coexists with heart failure, both involving inflammatory signaling and cardiac fibroblasts. To understand the role of fibroblast NLR family pyrin domain containing 3 (NLRP3) inflammasome in cardiac function, we found that NLRP3 was up-regulated in atrial fibroblasts from AF patients. Fibroblast-specific activation of NLRP3 in mice induced AF-promoting atrial myopathy and heart failure with diastolic dysfunction, accompanied by increased fibrosis, and reduced conduction velocity. Knockdown of NLRP3 prevented the AF-promoting atrial substrate and cardiomyopathy in the context of NLRP3 activation in fibroblasts. We identify the fibroblast NLRP3 inflammasome as a key pathway governing the promotion of proarrhythmic fibrosis in AF and cardiomyopathy.
Keywords: atrial cardiomyopathy; atrial fibrillation; cardiac fibroblast; fibrosis; inflammasome.
Copyright © 2025 The Authors. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Funding Support and Author Disclosures This study is supported by grants from National Institutes of Health (R01HL164838, R01HL136389 and R01HL163277 to Drs Dobrev and Li; and R01HL131517, R01HL089598, and R01HL160992 to Dr Dobrev), the American Heart Association (936111 to Dr Li, 23POST1013888 to Dr Yuan), the European Union (large-scale integrative project MAESTRIA, No. 965286 to Dr Dobrev), the Deutsche Forschungsgemeinschaft (Research Training Group 2989, project 517043330 to Dr Dobrev), and the Heart and Stroke Foundation of Canada (Operating Grant 18-0022032 to Dr Nattel), the Canadian Institutes of Health Research (Foundation Grant 148401 to Dr Nattel), and the ATC Gene Vector Core at Baylor College of Medicine. Drs Coarfa, Koirala, and Grimm were partially supported by The Cancer Prevention Institute of Texas grants RP210227 and RP200504, National Institutes of Health P30 shared resource grant CA125123, NIEHS grants P30 ES030285 and P42 ES027725, and NIMH grant R01MH134392. This project was assisted by core facilities at Baylor College of Medicine, including the Mouse Phenotyping Core (NIH UM1HG006348, R01DK114356, S10OD023380), the Pathology and Histology Core (HTAP, NCI P30CA125123), and the Single Cell Genomics Core (S10OD023469, S10OD025240, P30EY002520). Dr McClendon is a paid consultant by CoRegen, Inc. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Figures









References
Grants and funding
LinkOut - more resources
Full Text Sources